Awad Magbri*, Eussera El-Magbri and Mariam El-Magbri
Dialysis Access Center of Pittsburgh, PA, USA
Received Date: October 20, 2017; Accepted Date: October 27, 2017; Published Date: November 10, 2017
Citation: Magbri A , El-Magbri E, El- Magbri M (2017) Hepa to-Pulmonary Syndrome and Porto-Pulmonary Hypertension: Rare Combination Cause of Hypoxemia in Patient with End-St age Renal Failure on He modialysis and Hepatitis C Induce d Decompensated Cirrhosis. Acta Psychopathol 3:77. doi: 10.4172/2469-6676.100149
The combination of Hepato-pulmonary syndrome and porto-pulmonary hypertension is very rare in patients with cirrhosis. This case is presented with Hepato-pulmonary syndrome with ascites and Hepato-splenomegaly and evidence of pulmonary hypertension which may be due to the underlying liver disease and/ or the increased blood flow through the arterial-venous fistula that the patient has for end-stage renal disease treatment with hemo-dialysis. The treatment of both POPH and HPS when co-exist in the same patient is challenging. These patients usually, have multiple co-morbidities and are not candidates for liver transplantation. Even though, liver transplantation can cure both syndromes but is contra-indicated in patients with high POPH. Whether combined lung and liver transplantation can be used in patients with high POPH is a matter for discussion. More studies are needed to tackle the co-existence of both syndromes in patients with portal hypertension.
Hepato-pulmonary syndrome; Porto-pulmonary hypertension; Hypoxemia; Cirrhosis; End-stage renal disease; Contrast echocardiography; Pulmonary arterial pressure; Left ventricular end-diastolic volume; Pulmonary hypertension
The case is that of 83 year-old African American man with hypertension, hepatitis C induced decompensated cirrhosis with ascites, end-stage renal disease (ESRD) on hemodialysis, fluid overload with peripheral edema and chronic hypotension. The patient was referred to the dialysis access center of Pittsburgh, PA for evaluation of his prolonged bleeding from the left upper arm brachial-basilic arterial-venous fistula (BBAVF).
On examination, he was found to be severely hypoxic with oxygen saturation of 80-92 mm Hg. Chest was clear on auscultation. Abdominal examination showed hepatosplenomegaly with ascites. Extremities showed 3+ peripheral edema bilaterally. His chest x-ray showed cardiomegaly with clear lung fields. His laboratory workup showed, WBC of 3.4, RBC 3.69, MCH 31.2, MCHC 32, and platelets 104 K/L. Chemistry showed Na 134, Cl 99, CO2 24, Total protein 7.2 with albumin of 2.9. SGOT was high at 44, vitamin D 42. Laboratory data were also indicative of chronic liver disease with bilirubin of 2.8, INR of 1.2, and albumin of 2.9, and platelet count of 104. Immunology for Hepatitis B Ag was negative, Hepatitis B Ab was 22 H, Hepatitis C Ab was positive. Arterial blood gas analysis showed PaO2 of 54 mmHg while breathing room air.
Abdominal ultra-sound revealed features suggestive of portal hypertension (hepatosplenomegaly with ascites). Transthoracic echocardiogram showed elevated right ventricular systolic pressure of 52 mmHg with mild-moderate dilatation of the right atrium and right ventricle with normal left ventricular function. A contrast echocardiogram was suggestive of hepatopulmonary syndrome (appearance of the bubbles in the left ventricle after 5 beats of their appearance in the right ventricle). Right heart catheterization was not done but his angiogram revealed reflux of dye into the right innominate vein up to the subclavian vein and right IJ. Other causes of pulmonary hypertension were excluded on history and clinical examination.
Hepatic diseases are associated with 3 main pulmonary syndromes associated with portal hypertension:
1. Porto-pulmonary hypertension (POPH), pulmonary arterial hypertension in the absence of other causes.
2. Hepatopulmonary syndrome (HPS), pulmonary arterial vascular dilatation with a defect in arterial oxygenation.
3. Hepatic hydrothorax.
The incidence of POPH and HPS in patients with liver disease are (0-7%), and (4-29%) respectively . However, the co-existence of POPH and HPS is rare but has been previously reported in 2 case reports [1,2]. Many theories have been put forward to explain POPH and HPS related to pulmonary hemodynamic alteration in patients with liver diseases. One of these theory is up-regulation of inflammatory response in patients with portal hypertension which leads to increased endothelin receptors and vasoconstriction without hypoxemia . On the other hand, HPS is associated with vasodilation causing intra-pulmonary shunts of blood leading to hypoxemia [2,3]. It is ironic that both POPH and HPS can co-exist in the same patient as the underlying mechanisms are antagonistic. The explanation that have been circulating is that there is up-regulation of type B-endothelin receptors in HPS with increased nitric oxide and dilation of the pulmonary vessels with shunting and hypoxemia [2,3]. HPS is associated with hypoxemia in the up-right position and platypnea (dyspnea induced by up-right position and relived by recumbency). Measurement of SaO2 with portable pulse oximeter at ambient O2 partial pressure in supine position compared with upright position after 10 minutes can help in screening patients who might have HPS. The criteria for further additional tests rest on the followings ;
• SaO2 ≤ 92% in supine position
• A decrease in SaO2 of ≥ 4% after change from supine to the upright position (ΔSaO2)
If these criteria are met then patients undergo the following;
• Chest x-ray
• Pulmonary function test
• Trans-thoracic contrast enhanced echocardiography (CEE)
• Perfusion lung scan
In POPH, on the other hand there is up-regulation of A-type endothelin receptors leading to pulmonary arterial vasoconstriction causing vascular remodeling and development of pulmonary hypertension [1,3]. Dyspnea on exertion and increased pulmonary arterial pressure (PAP) in patients with portal hypertension are characteristics of POPH . Diagnosis is confirmed by right heart catheterization which showed;
i- Mean PAP >25 mmHg at rest, or >30 mmHg on exertion.
ii- Increased pulmonary vascular resistance >250 dyne/CM2.
iii- Trans-pulmonary gradient, the difference between mean PAP and pulmonary capillary wedge pressure (PCWP) >12 mmHg.
iv- Left ventricular end diastolic pressure of <15 mmHg in the absence of other causes of PAH .
Pulmonary hypertension (PH) is common in patients chronic kidney disease (CKD) stage-5 (9-39%) and end-stage renal disease on hemodialysis (18.8-68.8%), and (0-42%) in peritoneal dialysis [5-15]. Pulmonary hypertension in CKD-5 or ESRD on HD may be induced or aggravated by left ventricular dysfunction, volume overload [16-18], an arterial-venous fistula [7,11,19-23], sleep disorders [24-30], exposure to dialysis membranes , endothelial dysfunction , vascular calcification and stiffness, and severe anemia. Controlling volume overload and left ventricular disorders are important for relieving PH. Preventing PH in these patients are important because kidney transplant may not reverse the high mortality associated with established PH.
Diagnosis of HPS in patient with portal hypertension and hypoxemia is supported by the following;
1. PaO2 <80 mmHg
2. Alveolar-arterial gradient >15 mmHg on room air adjusted for age .
Treatment of POPH and HPS are different;
The mainstay of treatment of POPH is pulmonary vasodilation;
1. Intra-venous epoprostenol which causes improvement in hemodynamics and symptoms in POPH but needs constant intra-venous access for drug infusion and highly compliant patient .
2. Oral or nebulized prostacyclin .
3. Oral dual endothelin receptor antagonist (bosentan), which has beneficial effect on exercise capacity and hemodynamics in POPH .
Pulmonary hypertension in cirrhotic patients with portal hypertension carries a poor prognosis and high mortality after liver transplantation . A mean PAP of 50 mmHg is contraindication to liver transplantation . An aim of PAP of <35 mmHg is necessary if liver transplant is contemplated in cirrhotic patients . The 5-year survival of POPH is 14-45% of those receiving medical treatment. PH in ESRD patients is usually of the WHO class-II (PH secondary to left ventricular dysfunction). Vasodilator therapy which is currently is recommended for WHO class-I patients is contra-indicated in CKD-5 and ESRD because of increased mortality . PH due to left ventricular dysfunction has been ruled out in our patients because of low left ventricular end diastolic pressure however, the accuracy of echocardiography diagnosis in these cases is debatable.
Treatment of HPS is based on correction of hypoxemia with oxygen and liver transplantation which is the only measure to alter the natural course of the disease and improve the hypoxemia . However, persistent hypoxemia in patients with HPS carry a high morbidity and mortality in cirrhotic patients who contemplating liver transplantation . The 5-year survival of HPS without liver transplant is 23% .
The treatment of both POPH and HPS when co-exist in the same patient is challenging. These patients usually, have multiple co-morbidities and are not candidates for liver transplantation. Even though, liver transplantation can cure both syndromes but is contra-indicated in patients with high POPH. Whether combined lung and liver transplantation can be used in patients with high POPH is a matter for discussion. More studies are needed to tackle the co-existence of both syndromes in patients with portal hypertension.
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : February 20, 2019